The stability of treprostinil sodium after dilution in three common i.v. infusion vehicles was assessed. The chemical stability of treprostinil sodium was tested over a 48-hour period at 40 °C ...

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Revenue decreased by $3.5 million in 2024 compared to 2023, attributed to lower sales quantities linked to limitations on the availability of necessary pumps for administering Treprostinil Injection.

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial ...

New�Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups� �Data on Health Status Improvements Over Time Following Culture ...

Commercially available solutions of treprostinil sodium a, b were diluted in sterile water for injection, c 0.9% sodium chloride injection, d and 5% dextrose injection. e The concentrations tested ...

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened ...